Novavax has been granted a patent for coronavirus Spike proteins and nanoparticles for use in vaccines. The technology involves stable antigens surrounded by a detergent core, enhancing immunogenicity. The patent also covers dosages, formulations, and preparation methods. GlobalData’s report on Novavax gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Novavax Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Novavax, Anti-RSV vaccines was a key innovation area identified from patents. Novavax's grant share as of February 2024 was 52%. Grant share is based on the ratio of number of grants to total number of patents.

Coronavirus spike proteins for stable and immunogenic vaccines

Source: United States Patent and Trademark Office (USPTO). Credit: Novavax Inc

A recently granted patent (Publication Number: US11896664B2) discloses a non-naturally occurring spike glycoprotein of the SARS-CoV-2 virus with specific modifications aimed at enhancing its immunogenic properties. The modified CoV S glycoprotein includes an inactivated furin cleavage site and mutations at specific amino acid positions. The patent also covers an isolated host cell containing this modified glycoprotein, particularly insect cells like Sf9 cells, along with an isolated nucleic acid encoding the glycoprotein.

Furthermore, the patent describes an immunogenic composition comprising the modified CoV S glycoprotein and a pharmaceutically acceptable buffer. The composition can include specific amounts of the glycoprotein, a saponin adjuvant, and even a nanoparticle with a non-ionic detergent core. Methods for stimulating an immune response against SARS-CoV-2 in a subject by administering this immunogenic composition are also detailed, including dosage regimens and potential combinations with other immunogenic compositions. Overall, the patent aims to protect the unique modifications to the SARS-CoV-2 spike glycoprotein and their applications in developing effective vaccines or treatments against the virus.

To know more about GlobalData’s detailed insights on Novavax, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies